These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

827 related items for PubMed ID: 33167990

  • 1. Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study.
    Chen TH, Li YR, Chen SW, Lin YS, Sun CC, Chen DY, Mao CT, Wu M, Chang CH, Chu PH, Wu VC.
    Cardiovasc Diabetol; 2020 Nov 09; 19(1):189. PubMed ID: 33167990
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
    Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N.
    Circulation; 2018 Apr 03; 137(14):1450-1459. PubMed ID: 29133607
    [Abstract] [Full Text] [Related]

  • 3. Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor.
    Lee HF, Chen SW, Liu JR, Li PR, Wu LS, Chang SH, Yeh YH, Kuo CT, Chan YH, See LC.
    Cardiovasc Diabetol; 2020 Sep 30; 19(1):160. PubMed ID: 32998736
    [Abstract] [Full Text] [Related]

  • 4. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.
    Dave CV, Kim SC, Goldfine AB, Glynn RJ, Tong A, Patorno E.
    Circulation; 2021 Feb 23; 143(8):770-779. PubMed ID: 33302723
    [Abstract] [Full Text] [Related]

  • 5. Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study.
    Shin H, Schneeweiss S, Glynn RJ, Patorno E.
    Ann Intern Med; 2022 Jul 23; 175(7):927-937. PubMed ID: 35605236
    [Abstract] [Full Text] [Related]

  • 6. Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia.
    Real J, Vlacho B, Ortega E, Vallés JA, Mata-Cases M, Castelblanco E, Wittbrodt ET, Fenici P, Kosiborod M, Mauricio D, Franch-Nadal J.
    Cardiovasc Diabetol; 2021 Jul 09; 20(1):139. PubMed ID: 34243779
    [Abstract] [Full Text] [Related]

  • 7. Sodium Glucose Transporter 2 Inhibitors Versus Metformin on Cardiovascular and Renal Outcomes in Patients With Diabetes With Low Cardiovascular Risk: A Nationwide Cohort Study.
    Chang HC, Chen YY, Kuo TT, Lin YJ, Chien KL, Chang HY, Hung CL, Chung FP.
    J Am Heart Assoc; 2024 Apr 16; 13(8):e032397. PubMed ID: 38591334
    [Abstract] [Full Text] [Related]

  • 8. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D, Christiansen MN, Mogensen UM, Bundgaard JS, Rørth R, Madelaire C, Fosbøl EL, Schou M, Torp-Pedersen C, Gislason G, Køber L, Kristensen SL.
    Cardiovasc Diabetol; 2020 Jul 06; 19(1):107. PubMed ID: 32631337
    [Abstract] [Full Text] [Related]

  • 9. Sodium-Glucose Cotransporter-2 Inhibitors vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin.
    McCormick N, Yokose C, Lu N, Wexler DJ, Aviña-Zubieta JA, De Vera MA, McCoy RG, Choi HK.
    JAMA Intern Med; 2024 Jun 01; 184(6):650-660. PubMed ID: 38619822
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
    Gebrie D, Getnet D, Manyazewal T.
    Sci Rep; 2021 Jan 08; 11(1):137. PubMed ID: 33420333
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS.
    Circulation; 2019 Apr 23; 139(17):2022-2031. PubMed ID: 30786725
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor.
    Chan YH, Chen SW, Chao TF, Kao YW, Huang CY, Chu PH.
    Cardiovasc Diabetol; 2021 Apr 30; 20(1):93. PubMed ID: 33941171
    [Abstract] [Full Text] [Related]

  • 16. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
    Jang J, Park S, Kim S, Kim SH, Oh YS, Sa YK, Hwang Y, Jang SW, Ihm SH, Choi Y.
    Eur J Prev Cardiol; 2024 Feb 15; 31(3):320-329. PubMed ID: 37798123
    [Abstract] [Full Text] [Related]

  • 17. Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study.
    Shao SC, Chang KC, Hung MJ, Yang NI, Chan YY, Chen HY, Kao Yang YH, Lai EC.
    Cardiovasc Diabetol; 2019 Sep 24; 18(1):120. PubMed ID: 31551068
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study.
    Chan CW, Yu CL, Lin JC, Hsieh YC, Lin CC, Hung CY, Li CH, Liao YC, Lo CP, Huang JL, Lin CH, Wu TJ.
    Cardiovasc Diabetol; 2018 Jan 24; 17(1):20. PubMed ID: 29368615
    [Abstract] [Full Text] [Related]

  • 20. Clinical Outcomes in Type 2 Diabetes Patients After Acute Myocardial Infarction: A Comparison of Sodium-Glucose Cotransporter 2 Inhibitors vs. Non-Users.
    Lee HF, Chan YH, Hsu TJ, Chuang C, Li PR, Yeh YH, Su HC, Hsiao FC, See LC.
    Clin Pharmacol Ther; 2024 Aug 24; 116(2):426-434. PubMed ID: 38738997
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.